Sapreme Development B.V. to become Sapreme Therapeutics B.V.
As our company continues to evolve, we’re excited to announce that effective June 1st, 2026, Sapreme Development B.V. will become […]
Uncategorized
Uncategorized
Uncategorized
Sapreme Appoints CEO, BoD Chair and SAB to Advance Development of Next-Generation RNA Therapeutics for Genetically Driven Diseases
Bilthoven, The Netherlands, May 28, 2024 – Sapreme, a biotechnology company focused on developing next-generation RNA therapeutics for patients with